VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Zevra Therapeutics, Inc. (ZVRA) Total Return Calculator with Dividends Reinvested

Zevra Therapeutics, Inc.

Popular:

The total return for Zevra Therapeutics, Inc. (ZVRA) stock is +52.03% over the past 12 months. So far it's up 34.89% this year. The 5-year total return is +27.26%, meaning $10,000 invested in ZVRA stock 5 years ago would be worth $12,726 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in ZVRA 1 year ago, it would be worth $14,980 today — you'd have gained $4,980.

With Dividends Reinvested$14,980+49.80%

Price Only (No DRIP)$14,980+49.80%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in ZVRA

1Y$15,203+$5,203 (+52.0%)52.0% CAGR

3Y$22,866+$12,866 (+128.7%)31.7% CAGR

5Y$12,726+$2,726 (+27.3%)4.9% CAGR

10Y$1,018-$8,982 (-89.8%)-20.4% CAGR

15Y$628-$9,372 (-93.7%)-16.9% CAGR

20Y$628-$9,372 (-93.7%)-12.9% CAGR

30Y$628-$9,372 (-93.7%)-8.8% CAGR

Zevra Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading ZVRA total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+34.89%	—	+34.89%	—	$13,489
1Y	+52.03%	52.03%	+52.03%	—	$15,203
3Y	+128.66%	31.74%	+128.66%	—	$22,866
5Y	+27.26%	4.94%	+27.26%	—	$12,726
10Y	-89.82%	-20.43%	-89.82%	—	$1,018
15Y	-93.72%	-16.85%	-93.72%	—	$628
20Y	-93.72%	-12.93%	-93.72%	—	$628
30Y	-93.72%	-8.81%	-93.72%	—	$628

Risk & Highlights

Best Year+77.32%2015

Worst Year-83.99%2016

Max Drawdown-43.47%2025-07-15 → 2025-09-15

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+7.07%	+7.07%	—	+0.41%	+6.7pp
2025	+2.28%	+2.28%	—	+16.64%	-14.4pp
2024	+22.11%	+22.11%	—	+24.00%	-1.9pp
2023	+44.59%	+44.59%	—	+24.81%	+19.8pp
2022	-50.43%	-50.43%	—	-19.95%	-30.5pp

ZVRA outperformed the S&P 500 by 20.70pp over the past year (+52.03% vs +31.32%).

Loading summary...

ZVRA Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
ZVRAZevra Therapeutics, Inc.	$665M	+15.5%	+34.9%	+52.0%	—	+128.7%	+27.3%	-89.8%
RAREUltragenyx Pharmaceutical Inc.	$2.5B	+13.4%	+9.9%	-26.0%	—	-44.9%	-77.6%	-58.9%
FOLDAmicus Therapeutics, Inc.	$4.5B	+0.3%	+1.5%	+134.1%	—	+19.0%	+50.9%	+125.0%
ACADACADIA Pharmaceuticals Inc.	$3.7B	-3.8%	-17.9%	+47.7%	—	-0.3%	+2.5%	-22.3%
PTCTPTC Therapeutics, Inc.	$5.5B	-3.3%	-13.2%	+84.1%	—	+19.9%	+65.2%	+839.5%
KRYSKrystal Biotech, Inc.	$8.5B	+10.3%	+17.0%	+107.1%	—	+229.6%	+310.3%	+2615.2%
ACHCAcadia Healthcare Company, Inc.	$2.3B	+1.6%	+77.0%	+6.3%	—	-63.3%	-60.4%	-56.7%
ACRSAclaris Therapeutics, Inc.	$576M	+25.8%	+66.0%	+273.4%	—	-43.1%	-79.9%	-76.9%
MDGLMadrigal Pharmaceuticals, Inc.	$12.4B	+1.1%	-9.1%	+82.9%	—	+74.7%	+326.0%	+3755.2%
NKTRNektar Therapeutics	$1.7B	+13.9%	+96.0%	+783.6%	—	+636.7%	-69.4%	-57.6%
SUPNSupernus Pharmaceuticals, Inc.	$3.0B	+1.8%	+4.0%	+58.6%	—	+39.8%	+75.7%	+240.3%

Compare:ZVRA vs RARE ZVRA vs FOLD ZVRA vs ACAD ZVRA vs RARE vs FOLD

About ZVRA Dividend Returns

Zevra Therapeutics, Inc. (ZVRA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of ZVRA over the past year?

Zevra Therapeutics, Inc. (ZVRA) delivered a return of 52.03% over the past year. Since ZVRA does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in ZVRA be worth today?

A $10,000 investment in Zevra Therapeutics, Inc. one year ago would be worth $15,203 today, representing a gain of $5,203.

Q3Does ZVRA pay dividends?

Zevra Therapeutics, Inc. (ZVRA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ZVRA, the total return equals the price-only return.

Q4Did ZVRA beat the S&P 500?

Yes, Zevra Therapeutics, Inc. (ZVRA) outperformed the S&P 500 by 20.70 percentage points over the past year. ZVRA delivered a total return of 52.03%, compared to the S&P 500's 31.32%. This 20.70pp alpha means investors in ZVRA earned more than a passive S&P 500 index fund.

Q5What is ZVRA's worst drawdown?

Zevra Therapeutics, Inc. (ZVRA) experienced a maximum drawdown of -43.47% over the past year, declining from its peak on 2025-07-15 to its trough on 2025-09-15. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is ZVRA's long-term total return over 10, 20, or 30 years?

Here are Zevra Therapeutics, Inc. (ZVRA)'s long-term returns with dividends reinvested. Over 10 years, the total return is -89.8% (-20.4% CAGR) — $10,000 would have grown to $1,018. Over 20 years: -93.7% total return (-12.9% CAGR) — $10,000 → $628. Over 30 years: -93.7% total return (-8.8% CAGR) — $10,000 → $628. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was ZVRA's best and worst year?

Zevra Therapeutics, Inc.'s best calendar year was 2015 with a total return of 77.3%. Its worst year was 2016 with a total return of -84.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 161.3 percentage points.